Catheter-directed thrombolysis for intermediate-risk pulmonary embolism

Research output: Contribution to journalArticle

Abstract

Intermediate-risk pulmonary embolism is common and carries a risk of progression to hemodynamic collapse and death. Catheter-directed thrombolysis is an increasingly used treatment option, based largely on the assumptions that it is more efficacious than anticoagulation alone and safer than systemic thrombolysis. In this review, we critically analyze the published data regarding catheter-directed thrombolysis for the treatment of intermediate-risk pulmonary embolism. Catheter-directed thrombolysis reduces right heart strain and lowers pulmonary artery pressures more quickly than anticoagulation alone. The mortality for patients with intermediate-risk pulmonary embolism treated with catheter-directed thrombolysis is low, between 0% and 4%. However, similarly low mortality is seen with anticoagulation alone. Catheter-directed thrombolysis appears to be safer than systemic thrombolysis, and procedural complications are uncommon. Bleeding risk appears to be slightly higher than with anticoagulation alone. Randomized, controlled trials are needed to compare the efficacy and safety of catheter-directed thrombolysis versus anticoagulation for intermediate-risk pulmonary embolism. There is no evidence that catheter-directed thrombolysis decreases the incidence of chronic thromboembolic pulmonary hypertension. There is no evidence from clinical studies that ultrasound-assisted thrombolysis is more effective or safer than standard catheter-directed thrombolysis.

Original languageEnglish (US)
Pages (from-to)134-144
Number of pages11
JournalAnnals of the American Thoracic Society
Volume15
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Pulmonary Embolism
Catheters
Mortality
Pulmonary Hypertension
Pulmonary Artery
Randomized Controlled Trials
Hemodynamics
Hemorrhage
Safety
Pressure
Incidence
Therapeutics

Keywords

  • Catheter-directed thrombolysis
  • Pulmonary embolism
  • Thromboembolism

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Catheter-directed thrombolysis for intermediate-risk pulmonary embolism. / Furfaro, David; Stephens, Robert; Streiff, Michael B; Brower, Roy G.

In: Annals of the American Thoracic Society, Vol. 15, No. 2, 01.02.2018, p. 134-144.

Research output: Contribution to journalArticle

@article{3c8bcd38b59d4d0f8146c846e98416cc,
title = "Catheter-directed thrombolysis for intermediate-risk pulmonary embolism",
abstract = "Intermediate-risk pulmonary embolism is common and carries a risk of progression to hemodynamic collapse and death. Catheter-directed thrombolysis is an increasingly used treatment option, based largely on the assumptions that it is more efficacious than anticoagulation alone and safer than systemic thrombolysis. In this review, we critically analyze the published data regarding catheter-directed thrombolysis for the treatment of intermediate-risk pulmonary embolism. Catheter-directed thrombolysis reduces right heart strain and lowers pulmonary artery pressures more quickly than anticoagulation alone. The mortality for patients with intermediate-risk pulmonary embolism treated with catheter-directed thrombolysis is low, between 0{\%} and 4{\%}. However, similarly low mortality is seen with anticoagulation alone. Catheter-directed thrombolysis appears to be safer than systemic thrombolysis, and procedural complications are uncommon. Bleeding risk appears to be slightly higher than with anticoagulation alone. Randomized, controlled trials are needed to compare the efficacy and safety of catheter-directed thrombolysis versus anticoagulation for intermediate-risk pulmonary embolism. There is no evidence that catheter-directed thrombolysis decreases the incidence of chronic thromboembolic pulmonary hypertension. There is no evidence from clinical studies that ultrasound-assisted thrombolysis is more effective or safer than standard catheter-directed thrombolysis.",
keywords = "Catheter-directed thrombolysis, Pulmonary embolism, Thromboembolism",
author = "David Furfaro and Robert Stephens and Streiff, {Michael B} and Brower, {Roy G}",
year = "2018",
month = "2",
day = "1",
doi = "10.1513/AnnalsATS.201706-467FR",
language = "English (US)",
volume = "15",
pages = "134--144",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "2",

}

TY - JOUR

T1 - Catheter-directed thrombolysis for intermediate-risk pulmonary embolism

AU - Furfaro, David

AU - Stephens, Robert

AU - Streiff, Michael B

AU - Brower, Roy G

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Intermediate-risk pulmonary embolism is common and carries a risk of progression to hemodynamic collapse and death. Catheter-directed thrombolysis is an increasingly used treatment option, based largely on the assumptions that it is more efficacious than anticoagulation alone and safer than systemic thrombolysis. In this review, we critically analyze the published data regarding catheter-directed thrombolysis for the treatment of intermediate-risk pulmonary embolism. Catheter-directed thrombolysis reduces right heart strain and lowers pulmonary artery pressures more quickly than anticoagulation alone. The mortality for patients with intermediate-risk pulmonary embolism treated with catheter-directed thrombolysis is low, between 0% and 4%. However, similarly low mortality is seen with anticoagulation alone. Catheter-directed thrombolysis appears to be safer than systemic thrombolysis, and procedural complications are uncommon. Bleeding risk appears to be slightly higher than with anticoagulation alone. Randomized, controlled trials are needed to compare the efficacy and safety of catheter-directed thrombolysis versus anticoagulation for intermediate-risk pulmonary embolism. There is no evidence that catheter-directed thrombolysis decreases the incidence of chronic thromboembolic pulmonary hypertension. There is no evidence from clinical studies that ultrasound-assisted thrombolysis is more effective or safer than standard catheter-directed thrombolysis.

AB - Intermediate-risk pulmonary embolism is common and carries a risk of progression to hemodynamic collapse and death. Catheter-directed thrombolysis is an increasingly used treatment option, based largely on the assumptions that it is more efficacious than anticoagulation alone and safer than systemic thrombolysis. In this review, we critically analyze the published data regarding catheter-directed thrombolysis for the treatment of intermediate-risk pulmonary embolism. Catheter-directed thrombolysis reduces right heart strain and lowers pulmonary artery pressures more quickly than anticoagulation alone. The mortality for patients with intermediate-risk pulmonary embolism treated with catheter-directed thrombolysis is low, between 0% and 4%. However, similarly low mortality is seen with anticoagulation alone. Catheter-directed thrombolysis appears to be safer than systemic thrombolysis, and procedural complications are uncommon. Bleeding risk appears to be slightly higher than with anticoagulation alone. Randomized, controlled trials are needed to compare the efficacy and safety of catheter-directed thrombolysis versus anticoagulation for intermediate-risk pulmonary embolism. There is no evidence that catheter-directed thrombolysis decreases the incidence of chronic thromboembolic pulmonary hypertension. There is no evidence from clinical studies that ultrasound-assisted thrombolysis is more effective or safer than standard catheter-directed thrombolysis.

KW - Catheter-directed thrombolysis

KW - Pulmonary embolism

KW - Thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85045341722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045341722&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201706-467FR

DO - 10.1513/AnnalsATS.201706-467FR

M3 - Article

C2 - 29073366

AN - SCOPUS:85045341722

VL - 15

SP - 134

EP - 144

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - 2

ER -